1. Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case
- Author
-
Gabriella Fabbrocini, Gaia De Fata Salvatores, Elisa Camela, Luisa Abategiovanni, Adriana Di Guida, Mariateresa Nocerino, Claudio Marasca, Marasca, C., Fabbrocini, G., Abategiovanni, L., Camela, E., Nocerino, M., Di Guida, A., and De Fata Salvatores, G.
- Subjects
medicine.medical_specialty ,Acne fulminans ,business.industry ,Adalimumab ,Dermatology ,medicine.disease ,Acne fulminan ,Treatment ,Novel Insights from Clinical Practice ,medicine ,business ,Isotretinoin ,skin and connective tissue diseases ,Acne ,medicine.drug - Abstract
Acne fulminans (AF) is a rare, acute, and severe form of acne vulgaris often associated with systemic symptoms. Its treatment is challenging and controversial. We report a case of isotretinoin-induced AF (IIAF) in a 12-year-old boy resistant to traditional therapies (oral steroids and isotretinoin). The patient was successfully treated with adalimumab that can be considered an effective off-label option in the treatment of resistant IIAF in children.
- Published
- 2021